Nurix therapeutics to present preclinical data at upcoming 5th medicinal chemistry & protein degradation summit and 62nd ash annual meeting and exposition

San francisco, nov. 04, 2020 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present data on its novel targeted protein degradation platform at the upcoming 5th medicinal chemistry & protein degradation summit and preclinical data from its lead program, nx-2127, for the potential treatment of b-cell malignancies, at the 62nd american society of hematology (ash) annual meeting and exposition.
NRIX Ratings Summary
NRIX Quant Ranking